In last trading session, Keros Therapeutics Inc (NASDAQ:KROS) saw 0.4 million shares changing hands with its beta currently measuring 1.16. Company’s recent per share price level of $52.51 trading at -$1.17 or -2.18% at ring of the bell on the day assigns it a market valuation of $1.97B. That closing price of KROS’s stock is at a discount of -39.02% from its 52-week high price of $73.00 and is indicating a premium of 48.54% from its 52-week low price of $27.02. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.32 million shares which gives us an average trading volume of 366.41K if we extend that period to 3-months.

For Keros Therapeutics Inc (KROS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.27 in the current quarter.

Keros Therapeutics Inc (NASDAQ:KROS) trade information

Upright in the red during last session for losing -2.18%, in the last five days KROS remained trading in the green while hitting it’s week-highest on Thursday, 09/05/24 when the stock touched $52.51 price level, adding 4.54% to its value on the day. Keros Therapeutics Inc’s shares saw a change of 32.07% in year-to-date performance and have moved 15.89% in past 5-day. Keros Therapeutics Inc (NASDAQ:KROS) showed a performance of 15.66% in past 30-days. Number of shares sold short was 3.49 million shares which calculate 9.8 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 105 to the stock, which implies a rise of 49.99% to its current value. Analysts have been projecting 105 as a low price target for the stock while placing it at a high target of 105. It follows that stock’s current price would drop -99.96% in reaching the projected high whereas dropping to the targeted low would mean a loss of -99.96% for stock’s current value.

Keros Therapeutics Inc (KROS) estimates and forecasts

Statistics highlight that Keros Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -24.68% of value to its shares in past 6 months, showing an annual growth rate of 8.08% while that of industry is 17.90. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 3,357.00% from the last financial year’s standing.

And 10 analysts are in estimates of company making revenue of 5.64M in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -111.11% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 5.57% while estimates for its earnings growth in next 5 years are of 9.90%.

Keros Therapeutics Inc (NASDAQ:KROS)’s Major holders

Insiders are in possession of 5.86% of company’s total shares while institution are holding 99.19 percent of that, with stock having share float percentage of 105.37%. Investors also watch the number of corporate investors in a company very closely, which is 99.19% institutions for Keros Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at KROS for having 4.72 million shares of worth $215.69 million. And as of 2024-06-30, it was holding 16.0279 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 2.51 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.5348 of outstanding shares, having a total worth of $114.86 million.